Combination therapy for liver cancer after immunotherapy fails
Part of Cancer, Digestive system clinical trials.
This study is for people with advanced liver cancer whose previous immunotherapy (such as Keytruda or Tecentriq) is no longer working. It tests a new combination: chemotherapy infused directly into the liver, plus an immunotherapy drug and a targeted pill, to see if it can shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your advanced liver cancer (HCC) has been confirmed by imaging or biopsy.
- You have already tried at least one type of immunotherapy (like PD-1 or PD-L1 blockers) and it stopped working.
- You have not been treated with the targeted pill Regorafenib before.
- You have good liver function (liver category A) and a performance status that allows you to be up and active most of the day.
- You do not have any serious, ongoing side effects from past immunotherapy (like severe lung, gut, or skin problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (regorafenib) for people with advanced hepatocellular carcinoma (liver cancer) that has gotten worse after or during first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.